532983-04-3

Upstream product

• 488705-83-5 6-amino-1-(2,4-dichlorophenyl)-3-methyl-5-nitroso-2,4(1H,3H)-pyrimidinedione 
• 488705-85-7 5,6-diamino-1-(2,4-dichlorophenyl)-3-methyl-2,4(1H,3H)-pyrimidinedione 
• 488705-81-3 6-amino-1-(2,4-dichlorophenyl)-3-methyl-2,4(1H,3H)-pyrimidinedione 
• 5310-94-1 N-(2,4-dichlorophenyl)-N'-methyl-urea 
• 2612-57-9 2,4-dichlorophenyl isocyanate 
• 488705-87-9 3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6H- purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives as corticotropin-releasing factor1 receptor antagonists

A growing body of evidence suggests that CRF1 receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2, 6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF1 receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF1 antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.

3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands

Compounds provided herein are 3,7-dihydro-purine-2,6-dione derivatives of Formula (I): Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxi